DAY 1 (Thursday, Sept. 30, 2022)
Hybrid (F2F and Virtual)

(Wh)Y-EHTG Session
Our most dedicated Group of Young will surprise you in this session – stay tuned!

Best of Visual posters
Here the best selected abstracts will be presented orally in addition to an onsite/visual poster

Plenary Session (n=6)

1. Protecting fertility in patients with hereditary cancer syndromes
2. The actionable Microbiome?
3. Patient perspective – What do the patients value in risk management?
4. Cancer vaccines
5. to be selected from best abstracts
6. to be selected from best abstracts

Industry Symposium Lunch

Debates

1. Systematic tumor testing for genomic variants should be implemented (incl. costs-efficiency and capacity, RET pathogenic variants)
2. The term of oligo polyposis serves no purpose

Evolving Technologies

1. AI-assisted Pathology
2. AI-assisted Endoscopy
3. AI assisted Diagnosis

Welcome Reception
Included in the conference fee!
Accompanying persons to be registered at a low fee
DAY 2 (Friday, Sept. 3, 2022)

F2F and partially virtual

Three parallel working groups during the entire day
(9 in total, most favoured 3 Hybrid (F2F and virtual)

Working Group Topics
(9 going forward depending on quality abstracts)

1. Carcinogenic mechanisms and pathways
2. Surgical management of hereditary tumor syndromes
3. Gastroenterology
4. Genetics & Counselling
5. Surveillance & Clinical management
6. Immunology & Pathology
7. Epidemiology of hereditary cancer
8. MMR variant interpretation
9. EHTG Dynamic Guidance:
10. CMMRD
11. EOCRC
12. Microbiome
13. Hereditary cancer models and pathways
14. Systemic screening (liquid biopsies, urine, stool etc.)
15. Endocrine surgery

At the end of the day: Virtual Societies Meeting
DAY 3 (Saturday, Oct. 1, 2022)
Hybrid (F2F and Virtual)

WG Reporting Back

This important session will report back on all talks in the WG’s and the most important discussion points, aimed at identifying new collaborative studies. A MUST for all!

Plenary

Challenges of organizing European patient cancer registries for research (online)

Hot topics

ESCP-EHTG Joint Symposium
PDL1-Inhibitors versus Surgery for MSI Rectal cancers

Networking with patients and their organizations

Industry Symposium Lunch

Debates

1. Aspirin prevents more LS colorectal cancers than endoscopy
2. Molecular testing can direct management of colorectal cancer

EHTG Business Meeting and Farewell